{"title":"Amla提取物对体重指数、腰围、全身脂肪、内脏脂肪、骨骼肌质量、体年龄及相关参数的影响:一项随机、开放标签的肥胖受试者临床研究","authors":"Raksha Rathore, Ankia Yadav, Avni Khatkar, Deepa Suhag, Giriraja Kanakapura Vrushabaiah, Sumanraj Govindaraj","doi":"10.1159/000545247","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The escalating prevalence and severity of obesity and its associated co-morbidities globally necessitate effective interventions. This randomized open label clinical study aims to assess the efficacy of amla (Emblica officinalis) extract AMX-160 in adult individuals with obesity.</p><p><strong>Trial design: </strong>This study is a randomized, open-label clinical study conducted at Rajalakshmi hospital, Mangalore. The study adhered to the declaration of Helsinki and ICH-GCP guidelines, with protocol approval from institutional ethics committee and registration with the Clinical Trials Registry-India (CTRI/2019/01/017201). All participants provided written, signed, and dated informed consent before any study-related procedures.</p><p><strong>Methods: </strong>Forty obese patients were enrolled and divided into two groups. AMX-160 capsules, at doses of 500 mg once daily (AMX-M1) and twice daily (AMX-M2), were administered. Patients were monitored as outpatients for 90 days. Efficacy assessments included anthropometric measurements, Bioelectric Impedance analysis, lipid profile analysis, and the Global Physical Activity Questionnaire (GPAQ) at scheduled visits.</p><p><strong>Results: </strong>Supplementation with 1 gram of AMX-160 (500 mg twice daily) significantly (p<0.05) reduced visceral fat, increased skeletal muscle mass, and decreased subcutaneous fat. Additionally, it effectively decreased body age and various anthropometric parameters (e.g., waist circumference, waist-to-hip ratio) significantly (p<0.05), along with reducing BMI, body weight, and improving lipid profile (p<0.05). The 500 mg once daily dose also significantly (p<0.05) impacted most parameters. Physical activity levels remained consistent in both groups throughout the study (p>0.05).</p><p><strong>Conclusion: </strong>The amla extract AMX-160 (Tri-Low®) demonstrated efficacy in reducing subcutaneous and visceral fat, waist circumference, and body age, while increasing skeletal muscle mass. These findings suggest its potential as a supplement for managing obesity and its associated disorders.</p>","PeriodicalId":10541,"journal":{"name":"Complementary Medicine Research","volume":" ","pages":"1-22"},"PeriodicalIF":1.1000,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of Amla extract on Body Mass Index, waist circumference, total body fat, visceral fat, skeletal muscle mass, body age and related parameters: A randomized, open label clinical study in obese participants.\",\"authors\":\"Raksha Rathore, Ankia Yadav, Avni Khatkar, Deepa Suhag, Giriraja Kanakapura Vrushabaiah, Sumanraj Govindaraj\",\"doi\":\"10.1159/000545247\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The escalating prevalence and severity of obesity and its associated co-morbidities globally necessitate effective interventions. This randomized open label clinical study aims to assess the efficacy of amla (Emblica officinalis) extract AMX-160 in adult individuals with obesity.</p><p><strong>Trial design: </strong>This study is a randomized, open-label clinical study conducted at Rajalakshmi hospital, Mangalore. The study adhered to the declaration of Helsinki and ICH-GCP guidelines, with protocol approval from institutional ethics committee and registration with the Clinical Trials Registry-India (CTRI/2019/01/017201). All participants provided written, signed, and dated informed consent before any study-related procedures.</p><p><strong>Methods: </strong>Forty obese patients were enrolled and divided into two groups. AMX-160 capsules, at doses of 500 mg once daily (AMX-M1) and twice daily (AMX-M2), were administered. Patients were monitored as outpatients for 90 days. Efficacy assessments included anthropometric measurements, Bioelectric Impedance analysis, lipid profile analysis, and the Global Physical Activity Questionnaire (GPAQ) at scheduled visits.</p><p><strong>Results: </strong>Supplementation with 1 gram of AMX-160 (500 mg twice daily) significantly (p<0.05) reduced visceral fat, increased skeletal muscle mass, and decreased subcutaneous fat. Additionally, it effectively decreased body age and various anthropometric parameters (e.g., waist circumference, waist-to-hip ratio) significantly (p<0.05), along with reducing BMI, body weight, and improving lipid profile (p<0.05). The 500 mg once daily dose also significantly (p<0.05) impacted most parameters. Physical activity levels remained consistent in both groups throughout the study (p>0.05).</p><p><strong>Conclusion: </strong>The amla extract AMX-160 (Tri-Low®) demonstrated efficacy in reducing subcutaneous and visceral fat, waist circumference, and body age, while increasing skeletal muscle mass. These findings suggest its potential as a supplement for managing obesity and its associated disorders.</p>\",\"PeriodicalId\":10541,\"journal\":{\"name\":\"Complementary Medicine Research\",\"volume\":\" \",\"pages\":\"1-22\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2025-04-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Complementary Medicine Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000545247\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INTEGRATIVE & COMPLEMENTARY MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Complementary Medicine Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000545247","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}
Effect of Amla extract on Body Mass Index, waist circumference, total body fat, visceral fat, skeletal muscle mass, body age and related parameters: A randomized, open label clinical study in obese participants.
Background: The escalating prevalence and severity of obesity and its associated co-morbidities globally necessitate effective interventions. This randomized open label clinical study aims to assess the efficacy of amla (Emblica officinalis) extract AMX-160 in adult individuals with obesity.
Trial design: This study is a randomized, open-label clinical study conducted at Rajalakshmi hospital, Mangalore. The study adhered to the declaration of Helsinki and ICH-GCP guidelines, with protocol approval from institutional ethics committee and registration with the Clinical Trials Registry-India (CTRI/2019/01/017201). All participants provided written, signed, and dated informed consent before any study-related procedures.
Methods: Forty obese patients were enrolled and divided into two groups. AMX-160 capsules, at doses of 500 mg once daily (AMX-M1) and twice daily (AMX-M2), were administered. Patients were monitored as outpatients for 90 days. Efficacy assessments included anthropometric measurements, Bioelectric Impedance analysis, lipid profile analysis, and the Global Physical Activity Questionnaire (GPAQ) at scheduled visits.
Results: Supplementation with 1 gram of AMX-160 (500 mg twice daily) significantly (p<0.05) reduced visceral fat, increased skeletal muscle mass, and decreased subcutaneous fat. Additionally, it effectively decreased body age and various anthropometric parameters (e.g., waist circumference, waist-to-hip ratio) significantly (p<0.05), along with reducing BMI, body weight, and improving lipid profile (p<0.05). The 500 mg once daily dose also significantly (p<0.05) impacted most parameters. Physical activity levels remained consistent in both groups throughout the study (p>0.05).
Conclusion: The amla extract AMX-160 (Tri-Low®) demonstrated efficacy in reducing subcutaneous and visceral fat, waist circumference, and body age, while increasing skeletal muscle mass. These findings suggest its potential as a supplement for managing obesity and its associated disorders.
期刊介绍:
Aims and Scope
''Complementary Medicine Research'' is an international journal that aims to bridge the gap between conventional medicine and complementary/alternative medicine (CAM) on a sound scientific basis, promoting their mutual integration. Accordingly, experts of both conventional medicine and CAM medicine cooperate on the journal‘s editorial board, which accepts papers only after a rigorous peer-review process in order to maintain a high standard of scientific quality.
Spectrum of ''Complementary Medicine Research'':
- Review and Original Articles, Case Reports and Essays regarding complementary practice and methods
- Journal Club: Analysis and discussion of internationally published articles in complementary medicine
- Editorials of leading experts in complementary medicine
- Questions of complementary patient-centered care
- Education in complementary medicine
- Reports on important meetings and conferences
- Society Bulletins of Schweizerische Medizinische Gesellschaft für Phytotherapie (SMGP) and Deutsche Gesellschaft für Naturheilkunde
Bibliographic Details
Complementary Medicine Research
Journal Abbreviation: Complement Med Res
ISSN: 2504-2092 (Print)
e-ISSN: 2504-2106 (Online)
DOI: 10.1159/issn.2504-2092
www.karger.com/CMR